+

WO1994002613A1 - Vaccins contre le virus de l'immunodeficience anti-feline (vif) - Google Patents

Vaccins contre le virus de l'immunodeficience anti-feline (vif) Download PDF

Info

Publication number
WO1994002613A1
WO1994002613A1 PCT/EP1993/001861 EP9301861W WO9402613A1 WO 1994002613 A1 WO1994002613 A1 WO 1994002613A1 EP 9301861 W EP9301861 W EP 9301861W WO 9402613 A1 WO9402613 A1 WO 9402613A1
Authority
WO
WIPO (PCT)
Prior art keywords
fiv
polypeptide
protein
polypeptides
nucleic acid
Prior art date
Application number
PCT/EP1993/001861
Other languages
English (en)
Inventor
Albertus Dominicus Marcellinus Erasmus Osterhaus
Cornelus Herman Johannus Siebelink
Gustaaf Frank Rimmelzwaan
Original Assignee
Mallinckrodt Veterinary, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Veterinary, Inc. filed Critical Mallinckrodt Veterinary, Inc.
Priority to AU45693/93A priority Critical patent/AU4569393A/en
Publication of WO1994002613A1 publication Critical patent/WO1994002613A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to feline immuno ⁇ deficiency virus (FIV) and to the development of vaccines for use in protecting cats and kittens against FIV infection.
  • FIV feline immuno ⁇ deficiency virus
  • FIV is a recently discovered T-lymphotropic lentivirus which infects cats to produce an AIDS-like syndrome.
  • FIV while exhibiting morphological and pathological similarity, has however been shown to be antigenically distinct from the human immunodeficiency virus (HIV) (Pederson et al., Science 235: 790-793, 1987).
  • HIV human immunodeficiency virus
  • Infected cats and kittens show a generally debilitating AIDS-like disease with intermittent symptoms (eg. lymphadenopathy, leucopenia and anaemia) , characterised by a severe impairment of immune function as a result of loss of CD 4* T cells, resulting in susceptibility to secondary opportunistic infection and leading ultimately to death.
  • FIV shares with HIV and other mammalian len iviruses similarities in genome organisation, biological properties, the propensity for persistent infection in the natural host, with its concomitant pathological manifestations (eg. decline in CD4+ lymphocytes, both in vivo and in vitro, gradual loss of immune function, and opportunistic infection) .
  • pathological manifestations eg. decline in CD4+ lymphocytes, both in vivo and in vitro, gradual loss of immune function, and opportunistic infection.
  • FIV non-human lentivirus infections
  • the present invention is directed towards providing such a candidate vaccine.
  • the envelope glycoprotein of FIV is expressed initially as an 856 amino acid precursor protein having an estimated molecular weight of between about 130 kd and 160 kd which undergoes endoproteolytic cleavage to yield a mature complex, comprising in non-covalent association, an integral transmembrane glycoprotein (TM) of approximately 36-43 kd molecular weight and a peripheral outer membrane surface glycoprotein (SU) of estimated molecular weight 100-120 kd (Miyazawa et al., J. Virol., 65.: 1572-1577, 1991).
  • TM transmembrane glycoprotein
  • SU peripheral outer membrane surface glycoprotein
  • One aspect of the present invention accordingly provides a synthetic FIV polypeptide comprising an amino acid sequence substantially corresponding to all or a portion of the FIV envelope protein, or an antigenic fragment or functionally-equivalent variant thereof, in which the proteolytic cleavage site between the transmembrane and surface polypeptides of the native FIV envelope precursor protein has been eliminated and which comprises at least a portion of a transmembrane polypeptide and at least a portion of a surface polypeptide.
  • a further aspect of the invention provides such a synthetic FIV polypeptides and antigenic fragments and functionally-equivalent variants thereof for use in combatting FIV infection in animals, eg. mammals by stimulating an immune response against FIV.
  • the invention can also be seen to provide the use of such synthetic FIV polypeptides, and antigenic fragments and functionally equivalent variants thereof according to the present invention, in the preparation of a composition for combatting FIV infection in animals, eg. mammals, preferably for stimulating an immune response against FIV.
  • polypeptide as used herein defines both long chain polypeptides and shorter peptide sequences.
  • FIV polypeptide amino acid sequences As mentioned above, included within the scope of invention are functionally-equivalent variants and fragments of synthetic FIV polypeptide according to the invention.
  • “Functionally equivalent” as used above in relation to the polypeptide amino acid sequences defines polypeptides related to or derived from the native FIV envelope protein where the amino acid sequence has been modified by single or multiple amino acid substitution, addition or deletion, and also sequences where the amino acids have been chemically modified, including by glycosylation or deglycosylation, but which nonetheless retain im unogenic or other FIV-combatting activity eg. are capable of raising neutralising antibodies and/or functional immunity in the host.
  • Such functionally- equivalent variants may occur as natural biological variations or may be prepared using known techniques, for example functionally equivalent recombinant polypeptides may be prepared using the known techniques of site-directed mutagenesis, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids.
  • Modification of the amino acid sequences to obtain functionally-equivalent variant sequences may be by amino acid substitution, as long as the immunogenicity of the polypeptide is not affected.
  • an amino acid may be replaced by another which preserves the physicoche ical character of the polypeptide or its epitope(s) eg. in terms of charge density, hydrophilicity/hydrophobicity, size and configuration and hence preserve the immunological structure.
  • A may be replaced by G or vice versa, V by A, L or G; K by R; S by T or vice versa; E by D or vice versa; and Q by N or vice versa.
  • the substituting amino acid has similar properties eg. hydrophobicity, hydrophilicity, electronegativity, bulky side chains etc. to the amino acid being replaced.
  • Additional variants include amino and/or carboxyl terminal fusions, for example by addition of amino acid sequences of up to 300 eg. up to 200 or 100 residues, as
  • Amino acid sequences added may be those provided in the corresponding positions in the FIV envelope protein of other variants or other amino acids, eg. the whole or parts of other polypeptides or proteins.
  • Longer peptides may comprise multiple copies of one or more of the polypeptide sequences.
  • multiple copies of the polypeptides e.g. 5 to 20, preferably 8 to 15
  • MAPs multiple antigen peptides
  • Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product.
  • Deletional variants are characterised by the removal of one or more amino acids from the sequence.
  • deletions or insertions are made in adjacent pairs eg. a deletion of two residues or insertion of two molecules.
  • the proviso is that the modification preserves the immunogenicity of the polypeptide.
  • Exemplary functionally-equivalent variant polypeptides may thus include those displaying at least 50%, eg. at least 60 or 70%, or more preferably greater than 80% amino acid sequence homology. It should be noted however that functionally-equivalent variants, may exhibit overall sequence homology below the given percentages, but still fall within the scope of the present invention where they have conserved regions of homology.
  • cysteine residues at the termini of the polypeptides may be desirable to enable the polypeptides to mimic antigenic loops such as may appear on the surface of proteins and thereby enhance their immunogenicity.
  • a fatty acid or hydrophobic tail may also be added to the peptides to enhance immunogenicity and facilitate incorporation into delivery vehicles such as liposomes, novoso es and ISCOMS (Reid, Vaccine 10: 597-601, 1992).
  • the amino acid residues of the synthetic polypeptides of the invention may be chemically modified, particularly at the ends of the molecule, and may take the form, for example, of amino acid ester or amides.
  • N- or C-terminal residues, eg. N- or C- terminal, particularly C-terminal cysteine residues may be chemically blocked or protected for example by an acetamido or other protecting group.
  • a wide range of blocking groups are known in the art and may be used, including for example sulphonate, carboxymethyl, carboxamidomethyl, amino ethyl and similar groups.
  • the polypeptide may be linked to a carrier in order to create a conjugate which is immu ⁇ ogenically active.
  • a physiologically acceptable carrier may be employed, for example, a protein such as bovine serum albumin, thyroglobulin, ovalbumin or keyhole limpet hemocyanin.
  • yeast or the core protein from hepatitis virus (HBcAg) .
  • the polypeptide may also be linked to other FIV proteins or polypeptides thereby providing both an immunogen ar a multivalent vaccine at the same time.
  • a polypeptide may be prepared which itself incorporates an appropriate carrier sequence ie. as a fusion protein comprising the synthetic polypeptide(s) of the invention or a longer sequence incorporating such a polypeptide linked to a heterologous carrier sequence, as will be described in more detail below.
  • carrier proteins are generally chosen so that the resultant product is physiologically acceptable.
  • the synthetic polypeptides of the invention may be presented as pharmaceutically or physiologically acceptable salts eg. acid addition salts.
  • This may include both organic and inorganic salts such as those prepared for example from acids such as hydrochloric, hydrofluoric, sulfuric, sulfonic, tartaric, fumaric, hydrobromic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric, benzoic, ascorbic, p- toluenesulfonic, benzene-sulfonic, naphthalenesulfonic, propionic, and the like.
  • the acid addition salts are those prepared from hydrochloric acid, acetic acid, or succinic acid.
  • Such salts may be prepared by conventional methods well known to those skilled in the art.
  • the peptide may be converted into a carboxylic acid salt, such as an ammonium or alkali metal salt eg. a sodium, potassium, or lithium salt etc.
  • the synthetic FIV polypeptides according to the invention may be used to combat FIV infection in animals, and preferably to stimulate a host immune response against FIV.
  • a host immune response against FIV may comprise elements of both humoral and/or cell- mediated immunity to protect the host from FIV infection and/or kill or inhibit the virus, and may thus for example include the generation of immune effector molecules, antibodies or cells which damage, inhibit or kill the virus.
  • a host-protective immune response may be manifested by the generation of antibodies which are able to neutralise the virus.
  • One of the ways in which the synthetic FIV polypeptides of the invention may exert their host protective effects is by raising neutralising antibodies which inhibit the growth and/or maintenance of the virus.
  • neutralising antibodies which may be mono- or polyclonal, form a further aspect of the invention as do vaccine compositions containing them and their use in the preparation of vaccine compositions for passively immunising hosts against FIV infection.
  • Techniques for obtaining mono- or polyclonal antibodies are well known in the art.
  • FIV polypeptides according to the invention conveniently may be prepared by recombinant DNA technology using standard techniques such as those described for example by Sambrook et al., 1989, (Molecular Cloning, a Laboratory Manual, 2nd Edition, Cold Spring Harbour Press) .
  • a further aspect of the present invention thus provides a nucleic acid molecule comprising a nucleotide sequence substantially corresponding to all or a portion of the FIV env gene encoding the FIV envelope protein, or a sequence which is degenerate or substantially homologous with or which hybridises with any such aforesaid sequence, wherein in said nucleotide sequence the sequence encoding the proteolytic cleavage site between the transmembrane and surface polypeptides of the native FIV envelope protein has been eliminated, and wherein said nucleotide sequence encodes at least a portion of a transmembrane polypeptide and at least a portion of a surface polypeptide.
  • Additional aspects of the invention include such nucleic acid molecules for use in preparing FIV-combatting compositions eg. vaccine compositions for stimulating an immune response against FIV in animals, and the use of such nucleic acid molecules according to the invention in the preparation of FIV-combatting compositions eg. vaccine compositions for stimulating an immune response against FIV in animals.
  • Nucleic acid molecules according to the invention may be single or double stranded DNA, cDNA or RNA, preferably DNA.
  • Variations in the env coding region may occur between different isolates or serotypes, and strains of FIV of different geographical origin or even between different isolates from the same host and such variations which express as products capable of combatting FIV eg. by stimulating an immune response against FIV, are included in the scope of this invention.
  • Different FIV isolates and sequence divergence between them are described for example by Rigby et al.. in Journal of General Virology (1993) , 74 . , 425-436.
  • “Substantially homologous" as used herein includes those sequences having a sequence homology of approximately 60% or more, eg.
  • allelic variants and related sequences modified by single or multiple base substitution, addition and/or deletion.
  • functionally equivalent is meant nucleotide sequences which encode immunoreactive or immunogenic polypeptides eg. polypeptides which are capable of eliciting antibodies eg. neutralising antibodies or functional immunity in the host, or which otherwise are capable of combatting the FIV virus.
  • Nucleotide sequences as defined above which hybridise with regions of the FIV env gene, or with any degenerate, substantially homologous or functionally- equivalent sequence as defined above are also included within the scope of invention.
  • non-stringent conditions eg. 6 x SSC 50% formamide at room temperature
  • conditions of higher stringency eg. 2 x SSC, 65°C
  • SSC 0.15M Nacl 0.015M sodium citrate, pH 7.2
  • Provision of a nucleotide sequence according to the invention thus enables the recombinant FIV polypeptides to be obtained in significant quantities, thereby facilitating the development of anti-FIV vaccines and therapies.
  • Elimination of the proteolytic cleavage site in the nucleic acid molecules of the invention may conveniently be achieved by deletion or modification of the appropriate sequence coding for the cleavage site, for example by site-directed mutagenesis although other techniques may be used.
  • appropriate deletion may be achieved using site- directed mutagenesis for the construction of a recombinant vaccinia virus expressing the env gene of FIV, as will be described in more detail below.
  • VGR657 a recombinant vaccinia virus expressing the FIV env gene has been described by Rimmelzwaan et al, at the 1st International Conference of feline immunodeficiency virus researches held at U.C. Davis September 4-7, 1991 and is particularly suitable for use according to the present invention, but other vectors or expression systems, including for example other pox viruses (eg. fowl pox virus or canary pox virus) , feline rhinotracheitis, adenovirus, baculovirus and yeast, bacterial or mammalian expression systems may of course also be used.
  • pox viruses eg. fowl pox virus or canary pox virus
  • the nucleic acid molecules containing the cleavage site elimination according to the invention as defined above can be expressed in appropriate expression systems well known in the art, to obtain the recombinant FIV polypeptides of the invention.
  • the recombinant FIV polypeptides may thus be prepared by expression in a host cell containing a recombinant DNA molecule which comprises a nucleic acid molecule as broadly defined above, operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule.
  • the polypeptides may be expressed by direct injection of a naked DNA molecule comprising a nucleotide sequence according to the invention into a host cell. Appropriate recombinant DNA technology and expression techniques are, as mentioned above, well described in the literature for example in Sambrook et al., 1989 (Supra).
  • polypeptides so expressed may be fusion polypeptides comprising a FIV polypeptide according to the invention, and an additional polypeptide coded for by the DNA of the recombinant molecule fused thereto.
  • This may for example by 3-galactosidase, glutathione-S-transferase, yeast Ty particles, hepatitis core antigen, transmembrane portions of membrane proteins or any other of the polypeptides commonly employed in fusion proteins in the art.
  • aspects of the invention thus include cloning and expression vectors containing DNA comprising nucleotide sequences according to the invention and methods for preparing the nucleic acid molecules of the invention by inserting the said nucleotide sequences into vector nucleic acid, eg. vector DNA.
  • expression vectors include appropriate control sequences such as for example translational (eg. start and stop codes) and transcriptional control elements (eg. promoter-operator regions, ribosomal binding sites, termination stop sequences) linked in matching reading frame with the nucleic acid molecules of the invention.
  • the invention also includes transformed or transfected prokaryotic or eukaryotic host cells, or transgenic organisms containing a nucleotide sequence according to the invention as defined above, as well as methods for preparing synthetic polypeptides of the invention by culturing host cells containing a nucleic acid molecule as defined above under conditions whereby said polypeptide is expressed and recovering such polypeptide thus produced.
  • nucleic acid molecules which comprise nucleotide sequences according to the invention as defined above together with at least one additional flanking nucleotide sequence, which additional sequence may for example comprise 150 or more bases, preferably no more than 150 bases, more preferably no more than 100 eg. no more than 50 bases.
  • additional flanking sequences in the nucleic acid molecule according to the invention may be derived from the FIV env gene itself, from other regions of FIV DNA or from heterologous sources, and may be coding or non-coding. In a preferred aspect the flanking sequences may contain one or more restriction sites.
  • Cloning or expression vectors according to the invention may include plasmids, phage and recombinant viruses, according to techniques well known in the art and may be expressed in a variety of different expression systems cells, including bacterial (eg. E. coli) yeast or mammalian expression systems. To enable appropriate glycosylation of the FIV polypeptides of the invention to take place, expression in eukaryotic, preferably mammalian, systems is preferred.
  • the polypeptides according to the invention may thus be expressed in genetically engineered cell lines eg. cell lines (such as BHK or Hela) transfected with, for example, a virus vector, and capable of constitutively expressing the FIV polypeptides according to the invention.
  • a recombinant vaccinia virus As a convenient means of expression, a nucleic acid molecule according to this invention may be inserted into a plasmid vector downstream of a vaccinia virus promoter and flanked by vaccinia thymidine kinase (TK) sequences. The resultant recombinant vector is introduced into cells transfected with vaccinia virus. As a result of homologous recombination a TK recombinant vaccinia virus is generated which expresses the polypeptide.
  • TK thymidine kinase
  • Preferred expression systems according to the present invention include especially mammalian cell systems (eg. BHK cells) but also yeast, Baculovirus and bacterial systems such as E. coli or Salmonella.
  • Synthetic polypeptides according to the invention may also be prepared by chemical means, such as the well known Merrifield solid phase synthesis procedure.
  • nucleic acid sequences and polypeptides according to the invention may be used to prepare vaccine compositions using methods well known in the art of vaccine manufacture.
  • Traditional vaccine formulations may comprise one or more polypeptides according to the invention together, where appropriate, with one or more suitable adjuvants eg. aluminium hydroxide, muramyl dipeptide, mineral or vegetable oils, novosomes, liposomes, saponins, Quil-A, Q5-21, Matrix or pluronics, in the presence of one or more pharmaceutically acceptable carriers or diluents.
  • suitable carriers include liquid media such as saline solution appropriate for use as vehicles to introduce the polypeptides into a subject. Additional components such as preservatives may be included, as may other antigenic components such as other FIV antigens eg. other FIV proteins and/or polypeptides or other feline virus, eg feline leukaemia virus, antigens, to form a multivalent vaccine.
  • Immune stimulating complexes (ISCOMS Morein et al.. Nature, 308: 457-460, 1984) have recently been found to be particularly effective as adjuvants in vaccine preparations and are particularly attractive in presenting antigens which in native form are membrane bound.
  • TM transmembrane
  • ISCOMS are a preferred way of presenting the FIV polypeptide antigens according to the present invention.
  • ISCOMS are particularly effective in inducing both humoral (eg. virus neutralising antibodies) and cell-mediated immunity (eg. cytotoxic T-cells) .
  • Facilitation of ISCOM incorporation in this manner is believed to be due to retention of the highly hydrophobic TM portion of the envelope protein in the constructs of the invention. Accordingly presentation of antigens in this manner represents a particularly favoured and advantageous aspect of this invention.
  • Such vaccine compositions form a further aspect of the present invention, and the invention can thus be seen also to provide a composition for combatting FIV, preferably a vaccine composition for stimulating an immune response in an animal, preferably a mammal, against FIV, said composition comprising one or more FIV polypeptides comprising an amino acid sequence substantially corresponding to all or a portion of the FIV envelope protein, or an antigenic fragment or functionally-equivalent variant thereof, in which the proteolytic cleavage site between the transmembrane and surface polypeptides of the native FIV envelope precursor protein has been eliminated and which comprises at least a portion of a transmembrane polypeptide and at least a portion of a surface polypeptide, together with, optionally, one or more adjuvants, and a pharmaceutically acceptable carrier or diluent, and a method of combatting FIV, preferably a method of stimulating an immune response against FIV in an animal, eg. a mammal, comprising administering to said animal a composition as
  • An alternative favourable way of presenting the vaccine according to the invention is to administer to the animal an expression vector, capable of expressing the polypeptides in question such that the immunogenic polypeptides are expressed in situ in the animal.
  • an expression vector capable of expressing the polypeptides in question such that the immunogenic polypeptides are expressed in situ in the animal.
  • Such "in situ" expression of the antigenic polypeptides has been found to present the immunogen to the immune system of the animal in a particularly favourable manner, and immune responses elicited in this manner are generally significantly improved over those generated using more conventional techniques.
  • a further preferred aspect of the invention thus includes a composition for combatting FIV, preferably a vaccine composition for stimulating an immune response in an animal against FIV, said composition comprising an expression vector, or host cell having inserted therein a nucleotide sequence according to this invention for stimulation of an immune response directed against polypeptides encoded by the inserted nucleotide sequence, together with one or more pharmaceutically acceptable carrier or diluents.
  • Expression vectors suitable for such use are known in the art and include in particular viral vectors, notably pox virus vectors.
  • fusion protein may be expressed in such a system, where the heterologous protein part (the "carrier") comprises all or a portion of a transmembrane protein (eg. influenza virus HA) .
  • a transmembrane protein eg. influenza virus HA
  • the fusion protein When expressed in eukaryotic cells infected with such a recombinant virus, the fusion protein is generally glycosylated and transported to the cell surface through which it protrudes thereby presenting the synthetic polypeptides (or their epitopes) on the outside of the cell surface.
  • compositions eg. a vaccine composition according to the invention may take place by any of the conventional routes, eg. orally or parenterally such as by subcutaneous, intramuscular or intradermal injection, optionally at intervals eg. two injections at a 7-42 day interval.
  • a polypeptide is administered in an amount of 1 to 1000 ⁇ g per dose, more preferably 2 to 100 ⁇ g per dose.
  • Figure 1 is a plasmid map showing the construction of plasmid pGR657 used in the construction of recombinant vaccinia viruses (rW) ;
  • FIG. 2 shows the results of pulse chase analysis of the generation of FIV proteins after recombinant vaccinia virus (rW) infection of Hela cells.
  • rW vaccinia virus
  • Figure 3 shows a Western blot analysis of cell lysates of VSC65 (1), VGR657 (2) and VGR657X15 (3) infected BHK cells, using A) MoAb 6-13-12 and B) serum from FIV seropositive cat Adam 19; and
  • Figure 4 shows a Western blot analysis of ISCOMS prepared with lentil lectin chromatography purified lysates of VGR657 (1) and VGR657X15 (2) infected BHK cells, using A) MoAb 6-13-12 and B) serum from FIV seropositive cat Adam 19.
  • mice were immunized with ISCOMS in which FIV envelope proteins expressed by recombinant vaccinia virus VGR657 (Rimmelzwaan et al., 1991 supra and as described below) were trapped.
  • ISCOMS lysates of vGR657-infected RK13 cells were solubilized in phosphate buffered saline (PBS) containing 0.5% NP-40 and 0.5% SDS or 2% MEGA-10 (Boehringer Mannheim, Germany) . If the solution remained viscous, it was treated with DNAse in the presence of 2 mM MgCl.
  • glycoproteins were purified by affinity chromatography using lentil lectin sepharose (Pharmacia, Uppsala, Sweden) . Subsequently the purified protein was mixed with the lipids cholesterol and phospnatidyl-ethanolamine (Sigma, St. Louis, USA) and Quil A (Spikoside, ISCOTEC AB, Lulea, Sweden) at a ratio of 1:1:5 (w/w) and after ultrasonic treatment for 30 seconds incubated for one hour in the presence of 2% MEGA 10 (Boehringer Mannheim, Germany) .
  • Microtiter plates (Costar RIA/EIA, high binding) were coated with recombinant FIV glycoproteins obtained from lysates of vGR657-infected RK13 cells in 0.1 M NaAc buffer pH 5.5 for 16 hours at room temperature. Then the antigen was aspirated and the wells were fixed with 4% paraformaldehyde for 10 min at room temperature. After washing the plates with water containing 0.05% Tween 80 the plates were blocked with PBS containing 0.05% Tween 80 and 10% foetal calf serum (FCS) . Undiluted culture supernatants were transferred to the wells and incubated for one hour at 37"C.
  • FCS foetal calf serum
  • HRP horseradish peroxidase
  • Fc goat anti-mouse IgG
  • MoAb 6-12-13 a monoclonal antibody selected for these studies provided to be specific for the transmembrane (TM) protein of FIV as demonstrated by showing its reactivity with FIV env proteins in RIPA (see below and Fig. la) and immunostaining of Western blots (Fig. 2a and 3a) .
  • the FIV env gene (2.6 Kb) encoding the envelope precursor protein was amplified by PCR using bone marrow derived DNA, obtained from a FIV-infected cat as source of FIV proviral DNA (Siebelink et al., J. Virol, 66: 1091-1097, 1992).
  • the oligonucleotides in the PCR amplification were synthesized on an Applied Biosystems (Foster City, CA, USA) DNA synthesizer. Sequences of the oligonucleotides are as follows:
  • GGCAGTTGCAATCTACATTATC and GCAACAATAAGAATGGCAG (prime from the 5' end)
  • CTCAGCACAGTATCTCCC and GACATACCTTCCTCAAAGGG (prime from the 3' end) and were derived from the nucleotide sequence of the petaluma strain of FIV (Talbott et al., 1989, supra).
  • the amplified product was subsequently cloned into the Hinc II site of the E. coli cloning vector pBluescript II SK(+) (Stratagene, La Jolla, CA. USA) .
  • Insertion of the FIV env gene was confirmed by restriction endonuclease analysis, followed by DNA hybridization using gel purified env gene as labeled probe (ECL, Amersham, UK) and by shotgun sequencing of the FIV env gene.
  • the FIV env gene was excised from the Bluescript construct using restriction enzymes Xho 1 and Sma 1, and cloned into the Sal 1 and Sma 1 sites of plasmid pSC65 as shown in Figure 1.
  • pSC65 contains vaccinia virus TK sequences flanking the cloning site, a synthetic early/late vaccinia promotor and the lac Z gene under control of the vaccinia 7.5K promotor.
  • pGR657 fig. 1
  • Constructed plasmids were screened by restriction endonuclease analysis and DNA hybridization with gel purified env gene as labelled probe (ECL, Amersham, UK) , and were grown by standard procedures (Sambrook et al., 1989, supra).
  • rW vaccinia virus
  • the procedure to create recombinant vaccinia virus VGR657X15, containing a deletion in the nucleotide sequence at 1822-1833 positions coding for the cleavage site RRKR was as follows: 3 ⁇ g of the pBluescript construct containing the env gene (pBS/env) (Rimmelzwaan et al., 1991, supra) was used as template DNA for amplification by PCR using primers 5' - del (5* - GGAAGTCATGGAATATAAACCTGCAGCTATTCATGTTATGTTGGC-3• ; positions 1800-1856 in which positions 1822-1833 were deleted and 3' Bgl II (5 » -GGGGGTAGATCTTTTGTTTGGTTATACC- 3'; positions 2204-2227), to obtain fragment 5'-del/3'- Bgl II. Using primer pair 3'-del (reverse complementary to 5'-del) and 5'-NSI (5 « -
  • fragment 5'-NSl 1/3'-del was obtained.
  • a PCR was performed with the 5'-NSl 1 and 3'-Bgl II primers and 500 ng of the fragments 5'-NSl 1/3'-del and 5-'del/3'-Bgl II as template.
  • the PCR-derived 5'-NSll/ 3 '-Bgl II fragment was purified by preparative gel electrophoresis, digested with NS1 I and Bgl II and cloned into NS1 I/Bgl II digested pGR657.
  • the resulting plasmid was designated pGR657X15.
  • the presence of the deletion was confirmed by determination of the nucleotide sequence in this region using the dideoxynucleotide chain termination sequence reaction.
  • TK-143 B cells were infected with 30 pfu of recombinant vaccinia virus per cell and metabolically labeled for 18 hours with [ 35 S]methionine (ECL, Amersham, UK) .
  • Cells were lysed in PBS containing a 0.5% NP-40 and proteins .were immunoprecipitated as previously described using a serum from a cat infected with FIV (Chlody et al., AIDS Research and Retroviruses, 2(2) : 165-176, 1987). The proteins were analyzed by SDS-PAGE (Laemli 1970) .
  • infected cells were lysed 24 hours post-infection and proteins were separated by SDS-PAGE (Laemli 1970) and electrically transferred to nitrocellulose (Towbin) . After blocking the nitrocellulose sheets with PBS containing 0.1% Tween 80 and 0.5% milk-powder, they were incubated with either anti-FIV cat sera or monoclonal antibody.
  • nitrocellulose was incubated with biotin-labeled mouse anti-cat IgG (Clone CT-21, Sigma, St. Louis, USA) , or a goat anti-mouse IgG antibody preparation, respectively. Between each incubation the nitrocellulose was washed three times with PBS containing 0.5% Tween 80. Finally the blots were incubated with alkalic phosphatase (AP) complexed extravidin (Sigma, St. Louis, USA) followed by color reaction using BCIP/NTB as substrate.
  • AP alkalic phosphatase
  • the FIV proteins expressed by rW VGR657 and VGR657X15 were analysed by pulse-labeling in a radio immuno- precipitation assay (RIPA) and Western blot analysis.
  • RIPA radio immuno- precipitation assay
  • Hela cells were infected with recombinant vaccinia viruses VGR657, VGR657X15 or VSC65 (control rW made with pSC6S) at a multiplicity of infection (m.o.i) of 30 pfu per cell for 4 hours.
  • infected cells were incubated for 30 minutes in methionine- and cysteine- free medium (RPMI) prior to pulse-labeling for 30 minutes with 200 ⁇ Ci of [ 32 S] methionine/cysteine (specific activity >1000 Ci/mmol) per ml.
  • the pulse-labeling was followed by a chase period of 0.2, or 24 hours.
  • Culture supernatant as well as cell lysate was analysed for presence of FIV specific proteins. Culture supernatant was centrifugated to remove cells.
  • culture supernatant and cell lysate were incubated with serum from an FIV sero- negative cat and protein-A sepharose beads. After 1 hour incubation at 4°C the protein-A sepharose beads were removed by centrifugation. IgG from serum from an FIV sero positive cat was coupled to protein-A sepharose beads. After 1 hour the beads were washed twice with triton buffer (0.3 M NaCl; 50 mM Tris-HCl, pH 7.4 and 0.1% triton X-100 ® ).
  • triton buffer 0.3 M NaCl; 50 mM Tris-HCl, pH 7.4 and 0.1% triton X-100 ® .
  • This protein is subsequently cleaved into a protein of approximately MW 95,000 which is released in the culture supernatant and most likely represents the surface protein (SU) of FIV, and a protein of molecular weight approximately MW 32,000 which most likely represents the trans membrane protein (TM) of FIV and is cell-associated.
  • SU surface protein
  • TM trans membrane protein
  • the 130 kd protein could be visualized in VGR657X15 infected cells but not in VSC65 or VGR657 infected cells.
  • VGR657 infected cells the TM protein could be detected but not in vSC65 or VGR657X15 infected cells (Fig. 3) , which confirms the findings of the pulse labeling experiment.
  • the modified 130 kd envelope protein has been shown to sufficiently stable for ISCOM incorporation and is therefore proposed as a suitable candidate vaccine antigen for FIV.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à un polypeptide synthétique du VIF comprenant une séquence d'acides aminés correspondant pratiquement à tout ou partie de la protéine d'enveloppe du VIF, ou à un fragment antigénique ou une variante fonctionnellement équivalente de celui-ci, dans lequel le site de clivage protéolytique entre la transmembrane et les polypeptides de surface de la protéine précurseur d'enveloppe naturelle du VIF a été éliminé et qui comprend au moins une partie d'un polypeptide de transmembrane et au moins une partie d'un polypeptide de surface. L'invention se rapporte également à des molécules d'acide nucléique codant ces polypeptides, à des procédés pour leur expression recombinée, à des compositions de vaccins les contenant, et à leur utilisation pour lutter contre le VIF.
PCT/EP1993/001861 1992-07-17 1993-07-15 Vaccins contre le virus de l'immunodeficience anti-feline (vif) WO1994002613A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45693/93A AU4569393A (en) 1992-07-17 1993-07-15 Anti-feline immunodeficiency virus (fiv) vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929215233A GB9215233D0 (en) 1992-07-17 1992-07-17 Vaccines
GB9215233.9 1992-07-17

Publications (1)

Publication Number Publication Date
WO1994002613A1 true WO1994002613A1 (fr) 1994-02-03

Family

ID=10718888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/001861 WO1994002613A1 (fr) 1992-07-17 1993-07-15 Vaccins contre le virus de l'immunodeficience anti-feline (vif)

Country Status (4)

Country Link
AU (1) AU4569393A (fr)
GB (1) GB9215233D0 (fr)
WO (1) WO1994002613A1 (fr)
ZA (1) ZA935122B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040957A1 (fr) * 1995-06-07 1996-12-19 American Home Products Corporation Vaccins recombinants contre l'immunodeficience feline produits dans un baculovirus
WO1996040268A1 (fr) * 1995-06-07 1996-12-19 American Home Products Corporation Poxvirus recombines du raton laveur et leur utilisation en tant que vaccin efficace contre l'infection par le virus de l'immunodeficience feline
US5833993A (en) * 1994-04-29 1998-11-10 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
WO2002067984A3 (fr) * 2001-02-22 2002-12-12 Univ Florida Materiaux et methodes permettant de detecter, de prevenir et de traiter une infection retrovirale a vih ou a vif
EP1398325A1 (fr) * 2002-09-12 2004-03-17 Wyeth Anticorps monoclonal spécifique d'un épitope de glycoprotéine provenant d'un virus de l'immunodéficience féline inactivé

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245136A1 (fr) * 1986-04-08 1987-11-11 Transgene S.A. Vecteur viral, codant pour une glycoprotéine du virus responsable du SIDA, vaccin et anticorps
EP0335635A1 (fr) * 1988-03-28 1989-10-04 The Board Of Trustees Of The Leland Stanford Junior University Protéine de l'enveloppe d'HIV qui a subi une mutation
WO1992009632A1 (fr) * 1990-11-21 1992-06-11 Centre National De La Recherche Scientifique (Cnrs) Fragments de la proteine env du virus de l'immunodeficience feline, anticorps et leurs applications dans le diagnostic

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245136A1 (fr) * 1986-04-08 1987-11-11 Transgene S.A. Vecteur viral, codant pour une glycoprotéine du virus responsable du SIDA, vaccin et anticorps
EP0335635A1 (fr) * 1988-03-28 1989-10-04 The Board Of Trustees Of The Leland Stanford Junior University Protéine de l'enveloppe d'HIV qui a subi une mutation
WO1992009632A1 (fr) * 1990-11-21 1992-06-11 Centre National De La Recherche Scientifique (Cnrs) Fragments de la proteine env du virus de l'immunodeficience feline, anticorps et leurs applications dans le diagnostic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
File AIDSLINE, Abstract 00071711, INT. CONF. AIDS, 19-24 July 1992, 8(2)pA42, Abstract PoA 2237, G.F. RIMMELZWAAN et al., "Construction of Recombinant Vaccinia Viruses Expressing the Feline Immunodeficiency Virus (FIH) Env-Gene". *
JOURNAL OF VIROLOGY, Vol. 66, No. 2, February 1992, pages 1091-1097, K.H. SIEBELINK et al., "Isolation and Partial Characterization of Infectious Molecular Clones of Feline Immunodeficiency Virus Directly Obtained From Bone Marrow DNA of a Naturally Infected Cat". *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833993A (en) * 1994-04-29 1998-11-10 Pharmacia & Upjohn Company Feline immunodeficiency virus vaccine
US5989562A (en) * 1995-06-07 1999-11-23 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
WO1996040956A1 (fr) * 1995-06-07 1996-12-19 American Home Products Corporation Vaccins de recombinaison contre l'immunodeficience feline produits dans un baculovirus
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
WO1996040268A1 (fr) * 1995-06-07 1996-12-19 American Home Products Corporation Poxvirus recombines du raton laveur et leur utilisation en tant que vaccin efficace contre l'infection par le virus de l'immunodeficience feline
US5849303A (en) * 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
WO1996040957A1 (fr) * 1995-06-07 1996-12-19 American Home Products Corporation Vaccins recombinants contre l'immunodeficience feline produits dans un baculovirus
US6300118B1 (en) 1995-06-07 2001-10-09 American Home Products Corporation Plasmids comprising a genetically altered feline immunodeficiency virus genome
WO2002067984A3 (fr) * 2001-02-22 2002-12-12 Univ Florida Materiaux et methodes permettant de detecter, de prevenir et de traiter une infection retrovirale a vih ou a vif
US8182820B2 (en) 2001-02-22 2012-05-22 University Of Florida Research Foundation, Inc. Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens
US11154610B2 (en) 2001-02-22 2021-10-26 University Of Florida Research Foundation, Inc. Immunogenic compositions comprising FIV and HIV gag antigens
EP1398325A1 (fr) * 2002-09-12 2004-03-17 Wyeth Anticorps monoclonal spécifique d'un épitope de glycoprotéine provenant d'un virus de l'immunodéficience féline inactivé
US7345152B2 (en) 2002-09-12 2008-03-18 Wyeth Monoclonal antibody specific for an epitope of inactivated feline immunodeficiency-encoded glycoprotein
EP2281838A1 (fr) * 2002-09-12 2011-02-09 Wyeth LLC Anticorps monoclonal spécifique d'un épitope de glycoprotéine provenant d'un virus de l'immunodéficience féline inactivé

Also Published As

Publication number Publication date
AU4569393A (en) 1994-02-14
GB9215233D0 (en) 1992-09-02
ZA935122B (en) 1994-02-07

Similar Documents

Publication Publication Date Title
EP0755259B1 (fr) CLONES D'ADNc CHIMERES DU VIRUS DE LA BURSITE INFECTIEUSE, PRODUITS D'EXPRESSION ET VACCINS A BASE DESDITS CLONES
US5853724A (en) Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
US5352449A (en) Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
EP0546787A2 (fr) Expression d'immunogènes spécifiques utilisant des antigènes viraux
CZ375296A3 (en) Polynucleotide and vaccine containing thereof
EP0661999B1 (fr) Vaccins destines a lutter contre le virus immunodeficitaire felin
JP2009005706A (ja) 抗−ネコ免疫不全ウイルス（ｆｉｖ）ワクチン
KR101121754B1 (ko) Ｅ형 간염 바이러스의 폴리펩티드 단편, 그를 이용한 백신 조성물 및 진단용 키트
IE921875A1 (en) Vaccine and treatment method for human immunodeficiency¹virus
JP3829290B2 (ja) ニワトリ貧血症ウイルス変異体およびワクチン、ならびにウイルスタンパク質ｖｐ１、ｖｐ２およびｖｐ３またはウイルスをコードする配列に基づくそれらのための用途
KR0172970B1 (ko) Aids백신에 유용한 키메릭 단백 및 그의 제조방법
JPH01500161A (ja) Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン
Tami et al. Presentation of antigenic sites from foot-and-mouth disease virus on the surface of baculovirus and in the membrane of infected cells
WO1994002613A1 (fr) Vaccins contre le virus de l'immunodeficience anti-feline (vif)
US6284253B1 (en) Feline immunodeficiency virus (FIV) nucleotide sequence
EP0247904B1 (fr) Méthode de préparation et utilisation d'antigènes du virus de la leucémie des chats
CA2143187C (fr) Vaccins anti-virus d'immunodeficience chez les felins
WO1998022596A1 (fr) VIRUS VACCINAL RECOMBINE, PROCEDE POUR PREPARER UNE STRUCTURE PARTICULAIRE DE PROTEINES Gag A L'AIDE DE CELUI-CI, PARTICULE AINSI PREPAREE ET SON UTILISATION
WO2009053512A1 (fr) Protéines n, m, he du torovirus porcin, procédé d'obtention et leurs utilisations dans le diagnostic et le traitement de torovirus porcin
CN101440129A (zh) 抗hiv-1外膜嵌合蛋白的单克隆抗体
NO176996B (no) Fremgangsmåte for fremstilling av en farmasöytisk sammensetning for beskyttelse av felin leukemivirus (FeLV)
FR2593519A1 (fr) Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Ref country code: UZ

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)

Ref country code: UZ

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载